The MedAffairs Leaders Forum is widely-recognized as the place where medical affairs professionals obtain actionable insights to transform medical affairs into a function that truly adds-value to healthcare systems and especially patients. Attendees will network with experts and thought-leaders to understand issues like:

  1. Patient-centricity: How to change culture, add-value and put the patient at the center of the organization in practice
  2. Digital: Realizing the potential and the power that technology provides, whether it’s tapping unique external data sources, understanding patient needs through online patient communities, or enhancing R&D intelligence through Artificial Intelligence or Big Data.
  3. Communications: Leveraging both classical communications channels, such as publications or symposia, as well as social media, to ethically communicate evidence-based messages with key stakeholders.
  4. Real-world evidence and IITs: Working with External Experts, academic networks, registries or payers to achieve a more granular-level understanding of how a therapy works in the real world.
  5. Strategy and capabilities: Transforming medical affairs into a function that facilities the entire organization to be focused on satisfying stakeholder needs and enhancing the quality of evidence to truly add-value.
Request agenda here for complete speaker list

Large Pharma

Vice President, North America Medical Affairs Hospital Business
Pfizer Biopharmaceuticals Group

Vice President, Medical Lead, North America
Research, Development and Medical
Upjohn, a Pfizer Division

Global Head, Real World Evidence Strategy
Biogen

Director, Global Medical Affairs, Respiratory
Sanofi Genzyme

Senior Director, Global Medical Affairs, Rare Disease
Pfizer

Senior Director, Group Lead PEH HEOR
Patient and Health Impact
Pfizer

Global Medical Affairs Director
Reckitt Benckiser

Cardiovascular Metabolic Lead, US Medical Director
Pfizer

Field Analytics & Operations - Medical Affairs & Pipeline Teams
Genentech

Global Medical Lead, Patient Engagement Rare Diseases
Pfizer

Director, Epidemiology, Worldwide Safety
Pfizer

 

Small & Medium Pharma & Biotech

Chief Medical Officer
Histogenics Corporation

Vice President Medical Affairs
Vertex

Vice President Medical Sciences
Ovid Therapeutics

Chief Medical Officer, Surgical Products & Exogen
Bioventus

Executive Director-Medical Affairs
Achillion Pharmaceuticals

Head, Medical Science Liaisons and HEOR Liaisons Clinical Research and Medical Affairs
Sunovion Pharmaceuticals

Vice President, Head of Medical Affairs
Alkermes

Medical Director
Jazz Pharmaceuticals, Canada

Director, Clinical & Medical Affairs
Allena Pharma

 

MedTech & Diagnostics

Senior Vice President Payment & Health Care Delivery Policy
Advamed

Head Medical Affairs Global Medical and Scientific Affairs CPS
Roche Diagnostics International

Vice President Medical Affairs
Helius Medical

Vice President Medical Affairs
Foundation Medicine

Staff Data Scientist and Technical Fellow
Medtronic CRHF Clinical Research

Co-founder and Chief Medical Officer
Cloud DX

Medical Director, Clinical Studies Regulatory Affairs Manager Clinical Diagnostics
Thermo Fisher Scientific

Director, Market Access and Reimbursement Affairs
Luminex Corporation

Chief Medical Officer
Byteflies

 

Healthcare providers & Academics

Chief Digital Officer and Senior Vice President for Technology Innovation and Consumer Experience
Thomas Jefferson University and Jefferson Health System

President and Founder, Endo4Life
University of Memphis

 

Experienced Solution Providers

Senior Vice President Real World and Late Phase
Syneos Health

Principal, Real-World & Late Phase
Syneos Health

Senior Vice President, Business Partnerships
Within3

Request agenda here for complete speaker list

Pictures from recent MedAffairs Leaders Forum. Imagine being there...

This session focuses on Strategic Medical Affairs Management, specifically how Medical Affairs as a function can be at the forefront of offering added-value to key external and internal stakeholders. Furthermore, how Medical Affairs can become a strategic enabler for the entire organization by facilitating strong evidence and engagement that creates clear ROI. The issue of patient-centricity in practice will also be examined with perspectives, approaches and case studies presented. This will provide participants with actionable insights to help implement more patient-beneficial and focused activities that put the patient at the center of everything we do.

SPEAKER LIST - DAY 1

Vice President Medical Affairs
Vertex

Chief Medical Officer
Histogenics Corporation

Senior Director, Global Medical Affairs, Rare Disease
Pfizer

Global Medical Affairs Director
Reckitt Benckiser, UK

Vice President Medical Affairs
Foundation Medicine

Head, Medical Science Liaisons and HEOR Liaisons Clinical Research and Medical Affairs
Sunovion Pharmaceuticals

Senior Vice President, Business Partnerships
Within3

Cardiovascular Metabolic Lead, US Medical Director
Pfizer

Vice President, Head of Medical Affairs
Alkermes

Senior Vice President Real World and Late Phase
Syneos Health

Global Medical Lead, Patient Engagement Rare Diseases
Pfizer

Executive Director-Medical Affairs
Achillion Pharmaceuticals

 

Generating real-world evidence via observational studies, the use of patient registries or Investigator Initiated Trials (IITs) is one of the fastest growing areas of pharmaceutical R&D. Such post-marketing studies are becoming increasingly important as regulatory agencies demand more long-term data which demonstrates effectiveness from a clinical perspective, yet payers are also demanding evidence of economic value. The Medical Affairs unit plays a decisive role in generating this vital evidence and this stream will present solutions to the challenges companies face in generating high-quality evidence which will enable the communication of a compelling “value” argument to all external stakeholders.

SPEAKER LIST - DAY 2 - STREAM 1

Global Head, Real World Evidence Strategy
Biogen

Director, Epidemiology, Worldwide Safety
Pfizer

Senior Director, Group Lead PEH HEOR
Patient and Health Impact
Pfizer, USA

Principal, Real-World & Late Phase
Syneos Health

Staff Data Scientist and Technical Fellow
Medtronic CRHF Clinical Research

Chief Medical Officer, Surgical Products & Exogen
Bioventus, USA

Medical Director
Jazz Pharmaceuticals, Canada

Chief Medical Officer
Byteflies

Medical Affairs and MSL teams are increasingly looking to implement next generation medical communication practices. They need to offer essential evidence-based information to stakeholders on demand, through a variety of classical, yet also increasingly digital channels. This stream will focus on three key aspects of medical communication. Firstly, issues such as:
Protocol writing for internal late-phase studies and research initiatives; working with External Experts (KOLs) to enhance publications, abstracts & posters and receiving proposals for investigator-initiated studies. The second section of this day will focus on medical/scientific communications, including the review process, compliance issues, ensuring the claims made by marketing colleagues are justified and appropriately communicated and also effectively localized from global-level to country-level market requirements. The third area is looking at how the MSL can best be at the forefront of communicating the value message and engaging KOLs and other stakeholders.

 
SPEAKER LIST - DAY 2 - STREAM 2

Vice President, North America Medical Affairs Hospital Business
Pfizer Biopharmaceuticals Group

Director, Global Medical Affairs, Respiratory
Sanofi Genzyme

Vice President, Medical Lead, North America
Research, Development and Medical
Upjohn, a Pfizer Division

Chief Digital Officer and Senior Vice President for Technology Innovation and Consumer Experience
Thomas Jefferson University and Jefferson Health System, USA

Field Analytics & Operations - Medical Affairs & Pipeline Teams
Genentech

President and Founder, Endo4Life
University of Memphis

Vice President Medical Sciences
Ovid Therapeutics

Director, Clinical & Medical Affairs
Allena Pharma

This session focuses on the fast-evolving role of Medical Affairs specifically for MedTech companies and the increasingly important need for this function which facilitates overall corporate performance. The different business model of MedTech vs Pharma, necessitates an adjustment in the way KOLs, external experts & patients are engaged with and communicated to. This highly popular, 1-day stream is back and with new speakers, will enable the MedTech community to get the most out of their Medical Affairs teams and develop a more patient-centric business model.

SPEAKER LIST - DAY 3

Vice President Medical Affairs
Helius Medical 

Medical Director, Clinical Studies Regulatory Affairs Manager Clinical Diagnostics
Thermo Fisher Scientific

Co-founder and Chief Medical Officer
Cloud DX

Head Medical Affairs Global Medical and Scientific Affairs CPS
Roche Diagnostics International, Switzerland

Senior Vice President Payment & Health Care Delivery Policy
Advamed

Director, Market Access and Reimbursement Affairs
Luminex Corporation

PHARMA & MEDICAL DEVICE: VPs, Directors & Managers of:
Medical Affairs, Medical Science Liaisons, Medical Education, Health Outcomes & Liaison, Medical Communications, Marketing, KOL & Stakeholder Engagement, Late Phase & Real-World Research, Investigator-Initiated Research, Field HEOR, Field Medical, Scientific Affairs, Medical Advisors and Patient-Centricity.

Platinum Event Partner

Event Partners

Media Partners

This event is accredited for CPD (Continuing Professional Development) status

RECEIVE DISCOUNTED FLIGHTS WHEN YOU REGISTER FOR THIS EVENT WITH

Share with Colleagues